Global Blood Therapeutics, Inc. (GBT)
| Market Cap | 2.93B |
| Revenue (ttm) | 84.62M |
| Net Income (ttm) | -281.72M |
| Shares Out | 61.57M |
| EPS (ttm) | -4.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $47.49 |
| Previous Close | $48.34 |
| Change ($) | -0.85 |
| Change (%) | -1.76% |
| Day's Open | 48.85 |
| Day's Range | 47.21 - 49.25 |
| Day's Volume | 1,051,297 |
| 52-Week Range | 37.65 - 81.82 |
A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.
Global Blood Therapeutics ended 2020 with a nearly 40% drop in its share price. The pandemic negatively affected the number of Oxbryta prescriptions and therefore Oxbryta sales.
Since 2017, GBT has come a long way to gain Oxbryta approval for treating sickle cell disease. After over 100% capital gains, the stock gave up some profits as the market is sizing up Oxbryta'...
Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in F irst H alf of 2021
Final 72-Week Analyses of Phase 3 HOPE Study Demonstrat e Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in E...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate i...
GBT has the only approved drug that can completely reverse sickle cell disease, which is affecting over 250k people worldwide. It has been subjected to an unwarranted selloff due to a slower t...
Global Blood Therapeutics (GBT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Global Blood Therapeutics (GBT) news for Friday includes poor results from its third-quarter earnings report sending GBT stock lower. The post Global Blood Therapeutics News: 5 Things for GBT ...
Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2020 Results - Earnings Call Transcript
Global Blood (GBT) delivered earnings and revenue surprises of -34.72% and -17.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Achieved Oxbryta ® (voxelotor) net revenues of $ 36. 9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months o...
Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting Long-Term Use of Oxbryta ® ( voxelotor )
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on T...
Real-world effectiveness data on Oxbryta® (voxelotor) in the treatment of sickle cell disease featured as oral presentation
Smaller biotechs would make nice additions to pharma companies in similar areas of therapy
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Award ® for Industry Inn...
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2020, the compensation committee of GBT’s ...
Keynote Address by U.S. Assistant Secretary for Health Admiral Brett P. Giroir, M.D.
More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?
Global Blood Therapeutics (NASDAQ: GBT) shares are trading higher on Tuesday after Raymond James initiated coverage on the company's stock with an Outperform rating and announced a $115 price ...
Global Blood Therapeutics: Investment Risk Diminishing As Oxbryta Outperforms
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q2 2020 Results - Earnings Call Transcript
Global Blood (GBT) delivered earnings and revenue surprises of 27.12% and 67.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Achieved Oxbryta® (voxelotor) net revenues of $31.5 million, with approximately 1,000 new patient prescriptions
Seven top-ranked companies are poised to beat on earnings today after the closing bell.
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2020 financial results o...
Here are the best biotech stocks for investors looking for market-beating performance.
Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) have materially underperformed the broader biotech group, rendering its valuation attractive, according to Goldman Sachs.
SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle c...
Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.
Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease
Global Blood Therapeutic sees its Relative Strength Rating move into the 80-plus level.
Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.
New Drug Application submission, including new age-appropriate formulation, planned by mid-2021
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?
Here's why it is now a great opportunity to buy a company making an innovative therapy for patients with sickle cell disease.
Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2020, the compensation committee of GBT’s boa...
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q1 2020 Results - Earnings Call Transcript
Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Global Blood (GBT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
On Wednesday, investors will learn the progress of its sickle cell disease drug launch.
Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.
Global Blood Therapeutics: Key Catalysts Remain As The Search For Clinical Benefit Continues
Newly created GBT Community Fund to provide $150,000 in grants to U.S. non-profits addressing the needs of the sickle cell disease community
About GBT
Global Blood Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical tria... [Read more...]
| Industry Biotechnology | Founded 2011 |
| CEO Ted Love | Employees 352 |
| Stock Exchange NASDAQ | Ticker Symbol GBT |
Analyst Forecasts
According to 20 analysts, the average rating for GBT stock is "Buy." The 12-month stock price forecast is 86.47, which is an increase of 82.08% from the latest price.